1. TOX as a potential target for immunotherapy in lymphocytic malignancies
- Author
-
Shuxin Huang, Chaofeng Liang, Yangqiu Li, Yujie Zhao, and Shaohua Chen
- Subjects
HMG-box ,medicine.medical_treatment ,T cell ,Clinical Biochemistry ,Review ,Immune system ,fluids and secretions ,Medicine ,Immune biomarker ,Lymphocytic malignancies ,Transcription factor ,T cell exhaustion ,Thymocyte selection-associated HMG BOX ,business.industry ,Biochemistry (medical) ,lcsh:RM1-950 ,Immunotherapy ,Biological function ,Thymocyte ,medicine.anatomical_structure ,High-mobility group ,lcsh:Therapeutics. Pharmacology ,Cancer research ,Molecular Medicine ,Biomarker (medicine) ,bacteria ,business - Abstract
TOX (thymocyte selection-associated HMG BOX) is a member of a family of transcriptional factors that contain the highly conserved high mobility group box (HMG-box) region. Increasing studies have shown that TOX is involved in maintaining tumors and promoting T cell exhaustion. In this review, we summarized the biological functions of TOX and its contribution as related to lymphocytic malignancies. We also discussed the potential role of TOX as an immune biomarker and target in immunotherapy for hematological malignancies.
- Published
- 2021